» Articles » PMID: 32526193

Pulmonary Post-mortem Findings in a Series of COVID-19 Cases from Northern Italy: a Two-centre Descriptive Study

Abstract

Background: COVID-19 is characterised by respiratory symptoms, which deteriorate into respiratory failure in a substantial proportion of cases, requiring intensive care in up to a third of patients admitted to hospital. Analysis of the pathological features in the lung tissues of patients who have died with COVID-19 could help us to understand the disease pathogenesis and clinical outcomes.

Methods: We systematically analysed lung tissue samples from 38 patients who died from COVID-19 in two hospitals in northern Italy between Feb 29 and March 24, 2020. The most representative areas identified at macroscopic examination were selected, and tissue blocks (median seven, range five to nine) were taken from each lung and fixed in 10% buffered formalin for at least 48 h. Tissues were assessed with use of haematoxylin and eosin staining, immunohistochemical staining for inflammatory infiltrate and cellular components (including staining with antibodies against CD68, CD3, CD45, CD61, TTF1, p40, and Ki-67), and electron microscopy to identify virion localisation.

Findings: All cases showed features of the exudative and proliferative phases of diffuse alveolar damage, which included capillary congestion (in all cases), necrosis of pneumocytes (in all cases), hyaline membranes (in 33 cases), interstitial and intra-alveolar oedema (in 37 cases), type 2 pneumocyte hyperplasia (in all cases), squamous metaplasia with atypia (in 21 cases), and platelet-fibrin thrombi (in 33 cases). The inflammatory infiltrate, observed in all cases, was largely composed of macrophages in the alveolar lumina (in 24 cases) and lymphocytes in the interstitium (in 31 cases). Electron microscopy revealed that viral particles were predominantly located in the pneumocytes.

Interpretation: The predominant pattern of lung lesions in patients with COVID-19 patients is diffuse alveolar damage, as described in patients infected with severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses. Hyaline membrane formation and pneumocyte atypical hyperplasia are frequent. Importantly, the presence of platelet-fibrin thrombi in small arterial vessels is consistent with coagulopathy, which appears to be common in patients with COVID-19 and should be one of the main targets of therapy.

Funding: None.

Citing Articles

Complement activity and autophagy are dysregulated in the lungs of patients with nonresolvable COVID-19 requiring lung transplantation.

Shivshankar P, Mueller-Ortiz S, Domozhirov A, Bi W, Collum S, Doursout M Respir Res. 2025; 26(1):68.

PMID: 40016722 PMC: 11866606. DOI: 10.1186/s12931-025-03152-6.


SARS-CoV-2 enhances complement-mediated endothelial injury via the suppression of membrane complement regulatory proteins.

Wu J, Xu S, Li Z, Cong B, Yang Z, Yang Z Emerg Microbes Infect. 2025; 14(1):2467781.

PMID: 39945674 PMC: 11873982. DOI: 10.1080/22221751.2025.2467781.


Difference in Optical Coherence Tomography Angiography Parameters After SARS-CoV-2 Infection During the Alpha and Delta Variant Dominance Periods.

Kal M, Brzdek M, Karska-Basta I, Rzymski P, Pinna A, Mackiewicz J Viruses. 2025; 17(1).

PMID: 39861835 PMC: 11769401. DOI: 10.3390/v17010047.


Prospective and Longitudinal Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Positive and Negative Pneumonia: Potential Role of Decreased Naïve CD8 in COVID-19 Patients.

Bekbossynova M, Akhmaltdinova L, Dossybayeva K, Tauekelova A, Smagulova Z, Tsechoeva T Viruses. 2025; 17(1.

PMID: 39861830 PMC: 11768816. DOI: 10.3390/v17010041.


Utility of Protein Markers in COVID-19 Patients.

Alicia L, Maria Angeles O, Desiree M, Maximino R, Marilina G Int J Mol Sci. 2025; 26(2).

PMID: 39859366 PMC: 11766239. DOI: 10.3390/ijms26020653.


References
1.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

2.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View

3.
Kollias A, Kyriakoulis K, Dimakakos E, Poulakou G, Stergiou G, Syrigos K . Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020; 189(5):846-847. PMC: 7264537. DOI: 10.1111/bjh.16727. View

4.
Camprubi-Rimblas M, Tantinya N, Bringue J, Guillamat-Prats R, Artigas A . Anticoagulant therapy in acute respiratory distress syndrome. Ann Transl Med. 2018; 6(2):36. PMC: 5799142. DOI: 10.21037/atm.2018.01.08. View

5.
Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K . Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020; 92(5):491-494. PMC: 7166760. DOI: 10.1002/jmv.25709. View